Toggle Main Menu Toggle Search

Open Access padlockePrints

Clinical Burden of People with Symptomatic and Exacerbating COPD While on Triple Inhaled Therapy †

Lookup NU author(s): Professor Anthony De SoyzaORCiD

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

© 2025 by the authors.Background/Objectives: The burden of chronic obstructive pulmonary disease (COPD) in people who experience frequent moderate/severe exacerbations and frequent productive cough (FPC) while receiving triple inhaled therapy (TT) is poorly described. We aimed to examine clinical characteristics and patient-centric burden of this population. Methods: Data were drawn from the Adelphi COPD Disease-Specific Programme (DSP)™, a multinational cross-sectional survey on COPD (July 2022–January 2023). Patient characteristics and physician perceptions were described for the overall COPD cohort and subsets of those who were current/former Smokers, with ≥2 moderate or ≥1 severe Exacerbation(s) in the prior year while receiving TT and with FPC (SET+FPC) or without FPC (SET w/o FPC). Results: Of the overall cohort (N = 4372), 9.1% (n = 399) patients qualified for inclusion in the SET+FPC cohort; the mean (SD) age was 64.7 (10.9) and 69.1 (9.2) years, respectively. For the overall and SET+FPC cohorts, the mean (SD) number of exacerbations (prior year) was 1.1 (1.4) and 2.5 (1.4), respectively; median post-bronchodilator forced expiratory volume in 1 s (FEV1% predicted) was 68.0% and 49.0%, respectively, and physician-reported dyspnea grade (based on the modified Medical Research Council Dyspnea Scale) was ≥2 in 36.2% and 78.2%, respectively. Physicians were satisfied with COPD control in 76.1% of the overall and 39.6% of the SET+FPC cohorts. Conclusions: People with COPD who experience frequent moderate/severe exacerbations and FPC while receiving TT have substantial clinical and patient-centric burden and extensive unmet medical needs, suggesting inadequate disease control with current standard-of-care therapies.


Publication metadata

Author(s): De Soyza A, Nordon C, Coak E, Pennant T, Mullerova H, Fageras M, Alves JA, Janssens W

Publication type: Article

Publication status: Published

Journal: Journal of Clinical Medicine

Year: 2025

Volume: 14

Issue: 18

Online publication date: 15/09/2025

Acceptance date: 08/09/2025

Date deposited: 13/10/2025

ISSN (electronic): 2077-0383

Publisher: Multidisciplinary Digital Publishing Institute (MDPI)

URL: https://doi.org/10.3390/jcm14186488

DOI: 10.3390/jcm14186488

Data Access Statement: The authors confirm that the data supporting the findings of this study are available within the article.


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
AstraZeneca

Share